|Bid||231.23 x 1300|
|Ask||231.32 x 1200|
|Day's Range||230.13 - 232.80|
|52 Week Range||165.69 - 247.64|
|Beta (5Y Monthly)||0.78|
|PE Ratio (TTM)||46.91|
|Earnings Date||Apr 20, 2020 - Apr 26, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||262.16|
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced a new goal for its philanthropic initiative, Every Heartbeat Matters (EHM): to improve the lives of 2.5 million additional underserved structural heart and critical care patients by the end of 2025.
Edwards Lifesciences (EW) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Call it the democratization of the echocardiogram — as this young company's software enables more medical professionals to use the heart-image technology, it looks to nearly double staff in the next year.
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Last week, you might have seen that Edwards Lifesciences Corporation (NYSE:EW) released its annual result to the...
Edwards Lifesciences (EW) witnesses growth in TAVR procedures, led by strong therapy adoption across all geographies, particularly in the United States.
Dow Jones futures fell on coronavirus fears. Amazon stock surged on earnings, leading 3 stocks flashing possible buys. IBM CEO Ginni Rometty is leaving.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 30) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (NASDAQ: ...
Edwards Lifesciences (EW) delivered earnings and revenue surprises of -1.35% and 1.71%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Late Thursday, Edwards reported adjusted income of $1.46 per share on $1.17 billion in revenue for its fourth quarter ended Dec. 31. EW stock rose modestly in after-hours action.
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
Edwards Lifesciences (EW) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
A series of product launches despite the ongoing regulatory hurdles is likely to favor revenues in the medical products space this earnings season.
Robust customer adoption of the HemoSphere all-in-one monitoring platform is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.
Edwards Lifesciences stock tumbled Thursday after an analyst suggested sales of the company's heart-valve replacements, using a technique called TAVR, are experiencing a slowdown.